.The TSH receptor (TSHR) is a member of the glycoprotein hormone receptors, a subfamily of family A G protein-coupled receptors.The complex post-translational modifications of the TSH receptor (TSHR) include intramolecular cleavage and receptor multimerization. The thyroid gland's growth and functionality depend on TSHR and its endogenous ligand, thyrotropin (TSH), and the proper operation of the TSH/TSHR system is essential for the production and release of thyroid hormones.
Different G-protein subtypes and signaling pathways are activated by the TSHR, with Gs- and Gq-induced signaling likely having the greatest significance. Thyroid hormone synthesis and release in the thyroid gland require TSH and its receptor. The underlying cause of the various gain- or loss-of-function phenotypes connected to thyroid dysfunction is dysfunctions of the TSHR. It has been proposed that the TSHR plays a role in the etiology and pathophysiology of ophthalmopathy. A significant autoantigen for thyroid-related autoimmune diseases is TSHR. Additionally, a number of experimental drugs being developed have been suggested as potential targets for the treatment of thyroid cancer, including TSHR.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V19064 | NCGC00379308 (D3-βArr ) | 662164-09-2 | NCGC00379308, formerly known as D3-ßArr, is a Positive Allosteric Modulator (PAM) of the TSH receptor. | |
V86790 | SYD5115 | SYD5115 is an orally active TSH-R antagonist. | ||
V17547 | Carbimazole | 22232-54-8 | Carbimazole is an imidazole thyroid antagonist (antithyroid agent) that may be utilized in the research/study of Graves' disease. |